Among the N-heterocycles, imidazopyrazine structures [5–6], derived from amalgamation of privileged imidazole and pyrazine pharmacophores, are well represented in the area of medicinal chemistry since they possess pharmacological properties as mammalian target of rapamycin (mTOR) inhibitors [7], adenosine triphosphate (ATP) competitive inhibitors of the insuline-like growth factor 1 (IGF-1) receptor related to Ewing sarcoma [8], IGF-1 receptor inhibitors [9] or act as ligands on corticotropin releasing hormone (CRH) [10], γ-aminobutyric acid (GABA) [11] and melanocortin receptors [12]. This evidence concerns the gene CRH and Ewing sarcoma.